普沙托韋
外觀
臨床資料 | |
---|---|
商品名 | Presatovir |
法律規範狀態 | |
法律規範 |
|
識別資訊 | |
| |
CAS號 | 1353625-73-6 |
PubChem CID | |
化學資訊 | |
化學式 | C24H30ClN7O3S |
摩爾質量 | 532.1 |
3D模型(JSmol) | |
| |
|
普沙托韋(GS-5806,化學式C24H30ClN7O3S)是一種抗病毒藥,被開發用於治療呼吸道合胞病毒感染。它作為一種融合抑制劑,在II期臨床試驗中顯示出較好的療效。[1][2]
參見
[編輯]參考文獻
[編輯]- ^ Marty FM, Chemaly RF, Mullane KM, Lee DG, Hirsch HH, Small CB, et al. A Phase 2b, Randomized, Double-blind, Placebo-Controlled Multicenter Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of Presatovir in Hematopoietic Cell Transplant Recipients with Respiratory Syncytial Virus (RSV) Infection of the Lower Respiratory Tract. Clinical Infectious Diseases. December 2019. PMID 31915807. doi:10.1093/cid/ciz1167.
- ^ Stray K, Perron M, Porter DP, Anderson F, Lewis SA, Perry J, et al. Drug resistance assessment following administration of RSV fusion inhibitor presatovir to participants experimentally infected with respiratory syncytial virus. The Journal of Infectious Diseases. January 2020. PMID 31971597. doi:10.1093/infdis/jiaa028.